PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA.\', \'Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.\', \'Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.\', \'Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.\', \'Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA. ravetch@rockefeller.edu.\', \'Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA. sbournazos@rockefeller.edu.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41586-021-04017-w
?:hasPublicationType
?:journal
  • Nature
is ?:pmid of
?:pmid
?:pmid
  • 34547765
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 17.875
?:rankingScore_hIndex
  • 1052
is ?:relation_isRelatedTo_publication of
?:title
  • Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all